The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

Kolkhir, Pavel; Laires, P.A.; Salameh, Pascale; Asero, Riccardo; Bizjak, M; Košnik, Mitja; Dissemond, Joachim; Doorn, Martijn van; Hawro, Tomasz; Kasperska−Zając, Alicja; Zając, Magdalena; Kocatürk, Emek; Peter, Jonny; Parisi, Claudio Alberto Salvador; Ritchie, Carla; Kulthanan, Kanokvalai; Tuchinda, Papapit; Fomina, Daria; Kovalkova, Elena; Khoshkhui, Maryam; Kouzegaran, Samaneh; Papapostolou, Niki; Du‐Thanh, Aurélie; Kamegashira, Akiko; Vitchuk, Alexander; Bauer, Andrea; Grattan, Clive; Staubach, Petra; Bouillet, Laurence; Giménez‐Arnau, Ana; Maurer, Marcus; Weller, Karsten

doi:10.1016/j.jaip.2022.11.016

Cited by 17 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than half of the CRUSE ® users, 51.3%, reported angioedema. These results closely align with data already published from CURE and other real-world studies, where 72.4% of patients were female, the average age was 43.0 years, 40 and the rate of angioedema was 58.5% in patients with CSU. 9 patients with allergic rhinitis and asthma.…”

Section: Medication Use Patternssupporting

confidence: 90%

CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

Neisinger,

Sousa Pinto,

Ramanauskaite

et al. 2024

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

BackgroundChronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user‐friendly platform to complete patient‐reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.MethodsCRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real‐time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.ResultsCRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country‐specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second‐generation antihistamines were used in 74.0% of days.ConclusionsThe initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.

show abstract

Section: Medication Use Patternssupporting

confidence: 90%

CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

Neisinger,

Sousa Pinto,

Ramanauskaite

et al. 2024

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

show abstract

“…The reasons for this are unclear and need to be investigated. Complete disease control strongly relates to better sleep and quality of life as well as less impact on daily activities and work 21,22 . Treatment with omalizumab should only be stepped down in patients with complete control to see if spontaneous remission has occurred.…”

Section: Discussionmentioning

confidence: 99%

A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU study

Türk,

Kocatürk,

Ertaş

et al. 2024

Clinical & Translational All

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough there have been significant advances in the treatment of chronic spontaneous urticaria (CSU) in recent years, there remains a lack of clear guidance on when and how to step down treatment in responders. This study aims to investigate stepping down approaches of different steps of CSU treatment from a global perspective.Methods“Stepping down chronic spontaneous urticaria treatment” (SDown‐CSU) is an international, multicenter, observational, cross‐sectional, survey‐based study of the Urticaria Centers of Reference and Excellence (UCARE) network. The questionnaire included 48 questions completed by physicians in the UCARE network.ResultsSurveys completed by 103 physicians from 81 UCAREs and 34 countries were analyzed. Seventy‐eight percent of the participants responded that they had a national urticaria management guideline written by their professional societies and 28% responded that they had to operate under a regulatory guideline proposed by central health funding organizations. Seventy‐two and 58.7% of these national recommendations do not contain any detailed information on when and/or how CSU treatment should be discontinued. There was a lack of detailed information on antihistamines and cyclosporine in particular. A predefined maximum duration was generally not applicable to omalizumab and cyclosporine (81% and 82%, respectively). Nearly all UCAREs step down omalizumab within 6 months from the first controlled status and 42% discontinue cyclosporine after 6 months regardless of the control status.ConclusionsThe findings from the SDown‐CSU study clearly highlight a global need for guidance on the process of stepping down treatment in CSU. Additionally, the study offers a step‐down algorithm applicable to all stages of CSU treatment.

show abstract

“…Treatment targets in CSU entail complete symptom control (UAS7 = 0) and normalizing QoL. A UAS7 = 0 score is defined as “complete control”, yet many patients do not reach this target [ 3 , 16 ]; should we be asking whether this is an appropriate target for all patients with CSU? Moreover, a paradigm of “adjust, assess, and act” involves continuously assessing a patient’s disease status (using UCT) to determine whether treatment adjustments are required (Figs.…”

Section: Methodsmentioning

confidence: 99%

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

Armstrong

Soong

Bernstein

2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a complex skin disease characterized by the spontaneous appearance of wheals, angioedema, or both, for more than 6 weeks. Many patients experience a relapsing–remitting disease course for years. Owing to the unpredictability of wheal recurrence and the severity of pruritis, patients suffer considerable impairment in their quality of life. Physicians face multiple challenges, not least of which is a lack of clear guidance on what constitutes “treatment success”. There is a lack of awareness of which measures should be used to best assess the various aspects of CSU, including disease activity, disease control, and quality of life—which themselves each comprise multiple components—and how to apply the results of each score to treatment decision-making. Although the overarching aim of treatment is for patients to be completely free of signs and symptoms of CSU, a more realistic definition of “treatment success” is needed to guide ongoing, long-term disease management for each individual patient. In this review, we consider what lessons can be learned from the current evidence base to provide further direction toward a universal definition of “treatment success”.

show abstract

The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

Cited by 17 publications

References 42 publications

CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU study

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

Contact Info

Product

Resources

About

The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

Cited by 17 publications

References 42 publications

CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU study

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

Contact Info

Product

Resources

About

CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

CRUSE^®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria